Kant A - Search Results

1

Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?

Härmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, Kant A. Härmark L, et al. Among authors: kant a. Drug Saf. 2016 Oct;39(10):883-90. doi: 10.1007/s40264-016-0441-x. Drug Saf. 2016. PMID: 27379887

2

Web-based intensive monitoring of adverse events following influenza vaccination in general practice.

van Balveren-Slingerland L, Kant A, Härmark L. van Balveren-Slingerland L, et al. Among authors: kant a. Vaccine. 2015 May 5;33(19):2283-2288. doi: 10.1016/j.vaccine.2015.03.014. Epub 2015 Mar 20. Vaccine. 2015. PMID: 25797367 No abstract available.

3

Vitamin B₆ in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases.

van Hunsel F, van de Koppel S, van Puijenbroek E, Kant A. van Hunsel F, et al. Among authors: kant a. Drug Saf. 2018 Sep;41(9):859-869. doi: 10.1007/s40264-018-0664-0. Drug Saf. 2018. PMID: 29737502 Review.

4

Aim and Design of pREGnant, the Dutch Pregnancy Drug Register.

Vorstenbosch S, Te Winkel B, van Gelder MMHJ, Kant A, Roeleveld N, van Puijenbroek E. Vorstenbosch S, et al. Among authors: kant a. Drug Saf. 2019 Jan;42(1):1-12. doi: 10.1007/s40264-018-0722-7. Drug Saf. 2019. PMID: 30246225 Free PMC article.

5

Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.

Kant A, de Vries L, Rolfes L. Kant A, et al. Drug Saf. 2019 Jan;42(1):35-43. doi: 10.1007/s40264-018-0729-0. Drug Saf. 2019. PMID: 30284215

6

Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives.

Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Sultana J, et al. Among authors: kant a. Drug Saf. 2019 May;42(5):683-687. doi: 10.1007/s40264-018-0768-6. Drug Saf. 2019. PMID: 30565019 No abstract available.

7

Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD.

Weits G, Härmark L, Hartman J, Kant A. Weits G, et al. Among authors: kant a. Expert Opin Drug Saf. 2019 Apr;18(4):333-337. doi: 10.1080/14740338.2019.1591366. Epub 2019 Mar 14. Expert Opin Drug Saf. 2019. PMID: 30845849

8

Measuring the impact of pharmacovigilance activities, challenging but important.

van Hunsel F, Gardarsdottir H, de Boer A, Kant A. van Hunsel F, et al. Among authors: kant a. Br J Clin Pharmacol. 2019 Oct;85(10):2235-2237. doi: 10.1111/bcp.14042. Epub 2019 Jul 31. Br J Clin Pharmacol. 2019. PMID: 31368147 Free PMC article. No abstract available.

9

Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.

van Hunsel F, Peters L, Gardarsdottir H, Kant A. van Hunsel F, et al. Among authors: kant a. Drug Saf. 2021 May;44(5):589-600. doi: 10.1007/s40264-021-01047-1. Epub 2021 Feb 19. Drug Saf. 2021. PMID: 33606201

10

COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.

Rolfes L, Härmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. Rolfes L, et al. Among authors: kant a. Vaccine. 2022 Feb 11;40(7):970-976. doi: 10.1016/j.vaccine.2022.01.013. Epub 2022 Jan 17. Vaccine. 2022. PMID: 35067381 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

263 results

Search Page